- Home
- SA vs PCRX Comparison
SA vs PCRX Comparison
Compare SA & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SA
- PCRX
- Stock Information
- Founded
- SA 1979
- PCRX 2006
- Country
- SA Canada
- PCRX United States
- Employees
- SA N/A
- PCRX N/A
- Industry
- SA Precious Metals
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- SA Basic Materials
- PCRX Health Care
- Exchange
- SA Nasdaq
- PCRX Nasdaq
- Market Cap
- SA 1.0B
- PCRX 1.2B
- IPO Year
- SA N/A
- PCRX 2011
- Fundamental
- Price
- SA $14.56
- PCRX $24.10
- Analyst Decision
- SA
- PCRX Buy
- Analyst Count
- SA 0
- PCRX 9
- Target Price
- SA N/A
- PCRX $29.89
- AVG Volume (30 Days)
- SA 887.3K
- PCRX 569.4K
- Earning Date
- SA 08-12-2025
- PCRX 07-29-2025
- Dividend Yield
- SA N/A
- PCRX N/A
- EPS Growth
- SA N/A
- PCRX N/A
- EPS
- SA N/A
- PCRX N/A
- Revenue
- SA N/A
- PCRX $702,772,000.00
- Revenue This Year
- SA N/A
- PCRX $7.54
- Revenue Next Year
- SA N/A
- PCRX $10.78
- P/E Ratio
- SA N/A
- PCRX N/A
- Revenue Growth
- SA N/A
- PCRX 3.08
- 52 Week Low
- SA $9.40
- PCRX $11.16
- 52 Week High
- SA $20.55
- PCRX $29.61
- Technical
- Relative Strength Index (RSI)
- SA 66.60
- PCRX 36.99
- Support Level
- SA $14.26
- PCRX $23.99
- Resistance Level
- SA $15.17
- PCRX $24.90
- Average True Range (ATR)
- SA 0.49
- PCRX 0.88
- MACD
- SA 0.07
- PCRX -0.21
- Stochastic Oscillator
- SA 76.45
- PCRX 11.61
About SA Seabridge Gold Inc. (Canada)
Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.